COVID-19 Practice Resources

Information, practice tools and resources to support pharmacists throughout COVID-19.

• UPDATED Administration of COVID-19 Vaccine in Allergic or Immunosuppressed Patients: Evidence-based recommendations regarding the administration of COVID vaccines in patient populations who were excluded from initial clinical trials (March 2023)
• Workplace COVID-19 Rapid Testing
• COVID-19 Tests in Canada: Reference tool for pharmacists to understand and distinguish between approved COVID-19 testing methods and technologies.
• What Can Pharmacists Do Under the Controlled Drugs and Substances Act (CDSA) During the COVID-19 Pandemic? CPhA developed a series of practice tools to support pharmacists in their role as opioid stewards, using real-life provincial examples to show how pharmacists can manage opioid-related prescriptions under current CDSA exemptions to better care for vulnerable patients.
  • Accepting a Verbal Order (British Columbia example)
  • Adapting a Prescription (Ontario example)
  • Extending a Prescription (Newfoundland and Labrador example)
  • Transferring a Prescription (New Brunswick example)
• Resource Round-up: Childhood vaccination: Whether you’re administering vaccines in your pharmacy or helping parents and kids understand the benefits of getting vaccinated, there’s lots of information to wade through. Here is a round-up of some helpful resources.
• COVID-19 and vaccine hesitancy: CPhA has compiled a list of credible resources to help you address vaccine hesitancy with your patients.
• Vaccination FAQs: Answers to pharmacists’ most important questions about COVID-19 vaccines.
• Suggested Best Practices for Community Pharmacy: Providing Influenza Immunizations During the COVID-19 Pandemic: Working with its National Influenza Preparedness Working Group and informed by official guidance from the National Immunization Advisory Committee, CPhA has developed some suggested operational best practices to help community pharmacy plan for the upcoming influenza season.
• Supporting Pharmacists’ Mental Health and Wellness During COVID-19: This practice tool encourages pharmacists to be aware of their own mental health and well being during these challenging times, and provides practical tips and links to additional resources on where to get support.

Canadian Immunization Guide (CIG) chapter

• COVID-19 vaccine
• June 21, 2022: Summary of updates in the Canadian Immunization Guide: Updated guidance on COVID-19 vaccines in Canada

NACI statements

Current vaccine statements

• March 3, 2023: NACI Guidance on an additional COVID-19 booster dose in the spring of 2023 for individuals at high risk of severe illness due to COVID-19
  • Summary of NACI statement of March 3, 2023 (PDF)
• December 9, 2022: Updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration
  • Summary of NACI statement of December 9, 2022
• October 21, 2022: Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years
  • Summary of NACI statement of October 21
• October 7, 2022: Updated guidance on COVID-19 vaccine booster doses in Canada
  • Summary of NACI statement of October 7, 2022
• September 9, 2022: Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding
  • Summary of NACI statement of September 9, 2022
• September 1, 2022: Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines
  • Summary of NACI statement of September 1, 2022
• August 19, 2022: Recommendations on the use of a first booster dose of Pfizer-BioNTech Comirnaty COVID-19 vaccine in children 5 to 11 years of age
  • Summary of NACI statement of August 19, 2022 (PDF)
• July 14, 2022: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age (PDF)
  • Summary of NACI statement of July 14, 2022 (PDF)

Previous statements

• June 29, 2022: Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada (PDF)
  • Summary of NACI statement of June 29, 2022 (PDF)
• April 12, 2022: Updated guidance on a first booster dose of COVID-19 vaccines in Canada (PDF)
  • Summary of NACI statement of April 12, 2022 (PDF)
• April 5, 2022: Initial guidance on a second booster dose of COVID-19 vaccines in Canada (PDF)
  • Summary of NACI statement of April 5, 2022 (PDF)
• March 17, 2022: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 to 11 years of age
  • Summary of NACI statement of March 17, 2022
• March 11, 2022: Recommendations on the use of Medicago COVID-19 vaccine (Covifenz)
  • Summary of NACI statement of March 11, 2022
• February 17, 2022: Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine
  • Summary of NACI statement of February 17, 2022
• February 4, 2022: NACI rapid response: Updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2
  • Summary of NACI rapid response of February 4, 2022
• January 28, 2022: NACI rapid response: Guidance on the use of booster COVID-19 vaccine doses in adolescents 12 to 17 years of age
  • Summary of NACI rapid response of January 28, 2022

Archived material: As the environment and information surrounding the pandemic has evolved, we have archived a number of our resources and tools developed over the past year.